Adverse reactions following mass drug administration with diethylcarbamazine in lymphatic filariasis endemic areas in the northeast of brazil;Reações adversas após tratamento em massa com dietilcarbamazina em áreas endêmicas de filariose linfática no nordeste do brasil

Revista da Sociedade Brasileira de Medicina Tropical

Volumn 45, Issue 6, 2012, Pages 745-750

  Lima, Ana Wládia ^a   Medeiros, Zulma ^b   Dos Santos, Zailde Carvalho ^a   Da Costa, Gertrudes Monteiro ^c   Braga, Cynthia ^b  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c Secretaria de Saude do Recife   (Brazil)

Author keywords

Adverse drug reactions; Lymphatic filariasis; MDA program; Prevalence study

Indexed keywords

DIETHYLCARBAMAZINE;

ABSCESS; ADOLESCENT; ADULT; ADVERSE DRUG REACTION; ANOREXIA; ARTHRALGIA; ARTICLE; BRAZIL; CHILD; CHILL; CROSS-SECTIONAL STUDY; DIZZINESS; DROWSINESS; DRUG FEVER; DRUG INDUCED HEADACHE; ENDEMIC DISEASE; FEMALE; HUMAN; INTESTINE PARASITE; LETHARGY; LYMPHANGITIS; LYMPHATIC FILARIASIS; LYMPHEDEMA; MAJOR CLINICAL STUDY; MALE; NAUSEA; POPULATION RESEARCH; PRESCHOOL CHILD; PREVALENCE; RANDOM SAMPLE; SCHOOL CHILD; SCROTAL PAIN; SCROTAL SWELLING; SEX RATIO; SIDE EFFECT; STOMACH DISCOMFORT; STOMACH PAIN; SWEATING; URTICARIA; VOMITING;

ADOLESCENT; ADULT; ANIMALS; BRAZIL; CROSS-SECTIONAL STUDIES; DIETHYLCARBAMAZINE; ELEPHANTIASIS, FILARIAL; ENDEMIC DISEASES; FEMALE; FILARICIDES; HUMANS; MALE; PREVALENCE; YOUNG ADULT;

EID: 84872335932     PISSN: 00378682     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0037-86822012000600017     Document Type: Article

References (34)

1. Freitas H, Vieira JB, Braun R, Medeiros Z, Rocha EMM, Santos AAR, et al. Workshop para avaliação da situação epidemiológica da filariose linfática no Município de Belém, Pará, norte do Brasil. Rev Soc Bras Med Trop 2008; 41:212-216.
2. World Health Organization (WHO). Lymphatic Filariasis elimination. WHO; 2011.
3. World Health Organization. Global programme to eliminate lymphatic filariasis. Wkly Epidemiol Rec 2010; 85:365-372.
4. Ottesen EA, Duke BO, Karam M, Behbehani K. Strategies and tools for the control/elimination of lymphatic filariasis. Bull World Health Organ 1997; 75:491-503.
5. Babu BV, Mishra S. Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance. Trans R Soc Trop Med Hyg 2008; 102:1207-1213.
6. Nujum ZT. Coverage and compliance to mass drug administration for lymphatic filariasis elimination in a district of Kerala, India. International Health 2011; 3:22-26.
7. Cantey PT, Rao G, Rout J, Fox LM. Predictors of compliance with a mass drug administration programme for lymphatic filariasis in Orissa State, India 2008. Trop Med Int Health 2010; 15:224-231.
8. Horton J, Witt C, Ottesen EA, Lazdins JK, Addiss DG, Awadzi K, et al. An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis. Parasitology 2000; 121 (suppl I):147-160.
9. Ottesen EA. Efficacy of diethylcarbamazine in eradicating infection with lymphatic-dwelling filariae in humans. Rev Infect Dis 1985; 7:341-356.
10. Dreyer G, Noroes J. Diethylcarbamazine in the treatment of Bancroft's filariasis. Rev Soc Bras Med Trop 1997; 30:229-240.
11. Babu BV, Kar SK. Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Trop Med Int Health 2004; 9:702-709.
12. Babu BV, Nayak AN. Treatment costs and work time loss due to episodic adenolymphangitis in lymphatic filariasis patients in rural communities of Orissa, India. Trop Med Int Health 2003; 8:1102-1109.
13. McLaughlin SI, Radday J, Michel MC, Addiss DG, Beach MJ, Lammie PJ, et al. Frequency, severity, and costs of adverse reactions following mass treatment for lymphatic filariasis using diethylcarbamazine and albendazole in Leogane, Haiti, 2000. Am J Trop Med Hyg 2003; 68:568-573.
14. Babu BV, Rath K, Kerketta AS, Swain BK, Mishra S, Kar SK. Adverse reactions following mass drug administration during the Programme to Eliminate Lymphatic Filariasis in Orissa State, India. Trans R Soc Trop Med Hyg 2006; 100:464-469.
15. Medeiros Z, Gomes J, Beliz F, Coutinho A, Dreyer P, Dreyer G. Screening of army soldiers for Wuchereria bancrofti infection in the metropolitan Recife region, Brazil: implications for epidemiological surveillance. Trop Med Int Health 1999; 4:499-505.
16. Medeiros Z, Bonfim C, Alves A, Oliveira C, Netto MJ, Aguiar-Santos AM. The epidemiological delimitation of lymphatic filariasis in an endemic area of Brazil, 41 years after the first recorded case. Ann Trop Med Parasitol 2008; 102:509-519.
17. Albuquerque MF, Marzochi MC, Sabroza PC, Braga MC, Padilha T, Silva MC, et al. Bancroftian filariasis in two urban areas of Recife, Brazil: pre-control observations on infection and disease. Trans R Soc Trop Med Hyg 1995; 89:373-377.
18. Mattos D, Mota S, Dreyer G. Aspects of the social realities of children and adolescents seen at a reference service for bancroftian filariasis in Recife, state of Pernambuco. Rev Soc Bras Med Trop 2008; 41:29-35.
19. World Health Organization. Global programme to eliminate lymphatic filariasis: progress report on mass drug administration in 2008. Weekly epidemiological record 2009; 42:437-444.
20. Instituto Brasileiro de Geografia e Estatística (IBGE). Censo Demográfico 2000 [Internet]. Características da população e domicílios, resultados do universo da população. Brasília: IBGE; [cited 2011 May 5]. Available from: www.ibge.gov.br/home/estatistica/populacao/censo2000/.
21. World Health Organization (WHO). Lymphatic filariasis [Internet]. WHO; 2011 [2011 November 16]. Available from: http://www.who.int/lymphatic_filariasis/disease/en/
22. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, Flegal KM, Guo SS, Wei R, et al. CDC growth charts: United States: Adv Data; 2000. p. 1-27.
23. Bockarie MJ, Tisch DJ, Kastens W, Alexander ND, Dimber Z, Bockarie F, et al. Mass treatment to eliminate filariasis in Papua New Guinea. N Engl J Med 2002; 347:1841-1848.
24. El-Setouhy M, Abd Elaziz KM, Helmy H, Farid HA, Kamal HA, Ramzy RM, et al. The effect of compliance on the impact of mass drug administration for elimination of lymphatic filariasis in Egypt. Am J Trop Med Hyg 2007; 77:1069-1073.
25. Gunawardena S, Sri Ranganathan S, Fernandopulle R. Pharmacovigilance through consumer feedback (reporting) in the mass treatment of lymphatic filariasis using diethylcarbamazine and albendazole in two districts of Sri Lanka. Trop Med Int Health 2008; 13:1153-1158.
26. World Health Organization. Report on active surveillance for adverse events following the use of drug co-administrations in the global programme to eliminate lymphatic filariasis. Wkly Epidemiol Rec 2003; 78:315-317.
27. Dreyer G, Pires ML, Andrade LD, Lopes E, Medeiros Z, Tenorio J, et al. Tolerance of diethylcarbamazine by microfilaraemic and amicrofilaraemic individuals in an endemic area of Bancroftian filariasis, Recife, Brazil. Trans R Soc Trop Med Hyg 1994; 88:232-236.
28. Andrade LD, Medeiros Z, Pires ML, Pimentel A, Rocha A, Figueredo-Silva J, et al. Comparative efficacy of three different diethylcarbamazine regimens in lymphatic filariasis. Trans R Soc Trop Med Hyg 1995; 89:319-321.
29. Subramanyam Reddy G, Vengatesvarlou N, Das PK, Vanamail P, Vijayan AP, Kala S, et al. Tolerability and efficacy of single-dose diethyl carbamazine (DEC) or ivermectin in the clearance of Wuchereria bancrofti microfilaraemia in Pondicherry, south India. Trop Med Int Health 2000; 5:779-785.
30. Subramanyam Reddy G, Vengatesvarlou N, Das PK, Vanamail P, Vijayan AP, Kala S, et al. Tolerability and efficacy of single-dose diethyl carbamazine (DEC) or ivermectin in the clearance of Wuchereria bancrofti microfilaraemia in Pondicherry, south India. Trop Med Int Health 2000; 5:779-785.
31. Martin RM, Biswas PN, Freemantle SN, Pearce GL, Mann RD. Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies. Br J Clin Pharmacol 1998; 46:505-511.
32. Rodenburg EM, Stricker BHC, Visser LE. Sex-related differences in hospital admissions attributed to adverse drug reactions in the Netherlands. British J Clin Pharmacol 2010; 71:95-104.
33. Braga C, Dourado I, Ximenes R, Miranda J, Alexander N. Bancroftian filariasis in an endemic area of Brazil: differences between genders during puberty. Rev Soc Bras Med Trop 2005; 38:224-228.
34. Pani SP, Das LK, Vanamail P. Tolerability and efficacy of a three-age class dosage schedule of diethylcarbamazine citrate (DEC) in the treatment of microfilaria carriers of Wuchereria bancrofti and its implications in mass drug administration (MDA) strategy for elimination of lymphatic filariasis (LF). J Commun Dis 2005; 37:12-17.